Trial Profile

A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hexavalent Influenza mRNA vaccine Sanofi Pasteur (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Sanofi Pasteur

30 May 2025 Planned End Date changed from 1 May 2026 to 16 Apr 2026.
30 May 2025 Planned primary completion date changed from 1 May 2026 to 16 Apr 2026.
30 May 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com